Epigenomics

CENTOGENE to Participate in Upcoming Conferences in December

Retrieved on: 
Thursday, December 1, 2022
Growth, Diagnosis, Nature, Food, Physician, Instability, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Legislation, Epilepsy Phenome/Genome Project, Epigenomics, CLIA, Security (finance), Neurodegeneration, Metabolomics, Precision medicine, Risk, ISO, CAP, Drug discovery, Pharmaceutical industry, Proteomics

CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

Key Points: 
  • CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

Retrieved on: 
Monday, November 21, 2022
Growth, CFO, Diagnosis, Financial management, Nature, Science, Food, Physician, Instability, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Legislation, IPO, Mass meeting, Epilepsy Phenome/Genome Project, Élan, CLIA, Epigenomics, Security (finance), Neurodegeneration, Metabolomics, Supervisory board, KPMG, Precision medicine, Risk, Audit committee, ISO, CAP, Drug discovery, Property management, Pharmaceutical industry, Proteomics

Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.

Key Points: 
  • Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.
  • It is also planned that Ms. Sheahan will assume the role of Chair of the Audit Committee.
  • Ms. Sheahan currently serves as CFO of Avillion LLP, a private equity-backed life sciences company focused on the co-development and financing of pharmaceutical products.
  • We are very pleased to welcome Ms. Sheahan as a new member of the Supervisory Board, stated Peer Schatz, Chairman of the Supervisory Board of CENTOGENE.

Genomics Global Market Report 2022: Increasing Demand for Novel Therapeutics Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Genetics, Health, Genetic Alliance, Genetic disorder, Genomics, Molecular epidemiology, Infection, IHOP, Government, CDC, Cancer, Severe acute respiratory syndrome coronavirus 2, National Cancer Institute, University of Cambridge, Survivor, Biomarker, Functional genomics, USD, Biomarker discovery, Research, CRISPR, Pathway analysis, Nature, Chromosome, Metagenomics, National Centre for Disease Control, Disease, Whole genome sequencing, Therapy, Degenerative disease, Inherited disorders of trafficking, NGS, Illumina, Inc., Merck & Co., OGL, Gene, Antibiotics, Epigenomics

The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global genomics market size is expected to reach USD 94.9 billion by 2030.
  • The market is expected to register a CAGR of 16.4% in the forecast period owing to the increasing demand for novel therapeutics and research applications in genomics.
  • Functional genomics held the largest market share in the year 2021, owing to the demand for rising applications in diagnostics and gene therapy.

EQS-News: ​​​​​​​Epigenomics AG reports financial results for the first nine months 2022

Retrieved on: 
Friday, November 11, 2022
Epigenomics AG, Institutional review board, CET, Marketing, Federal Executive Boards, Liver cancer, Center, Aktiengesellschaft, Food, Board of directors, Webcast, Colorectal cancer, Technology, Sale, Board, COVID-19, AG, Trial of the century, Regulation of tobacco by the U.S. Food and Drug Administration, Biobank, FSE, DNA, Goal, EBITDA, OTCQX, CE marking, Company, CRC, Cancer, ECX, Clinical trial, Centers for Medicare & Medicaid Services, Research, Medicare, Patient, CEO, Center for Medicare and Medicaid Innovation, News, EDT, AGM, CMS, FDA, Income, Security (finance), Film, Pharmaceutical industry, Petroleum jelly, Cryptocurrency, Online shopping, Epigenomics, EUR

Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.

Key Points: 
  • Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.
  • Sales, general and administrative expenses decreased from EUR 5,809 thousand in the previous year to EUR 5,315 thousand in the first nine months of 2022.
  • The financial report for the first nine months of 2022 can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
  • Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).

CENTOGENE to Participate in Upcoming Conferences in November

Retrieved on: 
Thursday, November 10, 2022
CLIA, Nature, U.S. Securities and Exchange Commission, CAP, Food, Risk, Diagnosis, Drug discovery, Epilepsy Phenome/Genome Project, Legislation, Regulation of tobacco by the U.S. Food and Drug Administration, Precision medicine, SEC, ISO, Conference, Patient, Physician, Growth, Epigenomics, Security (finance), Metabolomics, Instability, Industry, Neurodegeneration, Pharmaceutical industry, Proteomics

CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

Key Points: 
  • CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

Retrieved on: 
Thursday, November 3, 2022
Precision medicine, Company, Research, Therapy, Growth, MIT, Hospital, Food, GDPR, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, GLOBE, FDA, BC, Legislation, Epilepsy Phenome/Genome Project, Nasdaq, CAP, Data analysis, Nature, CEO, Metabolomics, Physician, ISO, U.S. Securities and Exchange Commission, CLIA, Data, Medicine, Privacy, Acceleration, Partnership, R, Technology, Pharmacy, Security (finance), Epigenomics, SEC, Drug discovery, Diagnosis, Patient, Neurodegeneration, Solution, Pharmaceutical industry, Medical device, Risk management, Proteomics

and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.
  • At CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery, development, and commercialization, said Kim Stratton, Chief Executive Officer at CENTOGENE.
  • Ultimately, we want to heal the world of rare and neurodegenerative diseases, and we believe offering greater access to the CENTOGENE Biodatabank will accelerate bringing potentially life-saving therapeutics to patients around the world.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.

Bluestar Genomics Presents Positive Results From Validation Study in Pancreatic Cancer Detection at American Pancreatic Association (APA) Annual Meeting

Retrieved on: 
Wednesday, November 2, 2022
Oncology, Medical Supplies, Health, Diabetes, Genetics, Biotechnology, Statistics, DNA, Pancreatic cancer, Population, Diabetes, Cancer, Method, Genomics, Risk, Program, Disease, Epigenomics, Type 2, Blue star, Type 2 diabetes, San Francisco Bay Area, Patient, Biology, Ageing, Diagnosis, Medical imaging, Pharmaceutical industry

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced the results of a validation study for its early pancreatic cancer detection test.

Key Points: 
  • Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced the results of a validation study for its early pancreatic cancer detection test.
  • Bluestar Genomics epigenomics-based pancreatic cancer signal detection test assesses whether an individual has an abnormal DNA signal associated with pancreatic cancer by measuring levels of the biomarker 5-hydroxymethylcytosine (5hmC).
  • Its study cohort included patients recently diagnosed with Type 2 diabetes, a population with eight times the risk of developing pancreatic cancer.
  • Bluestar Genomics has built a body of scientific and clinical evidence demonstrating the scientific validity and clinical application of its 5hmC-based approach to pancreatic cancer detection.

Bluestar Genomics Receives CAP Accreditation for Its Clinical Laboratory

Retrieved on: 
Monday, October 10, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, CAP, Physician, Method, Pancreatic cancer, CLIA, Disease, Accreditation, Patient, Biology, Program, Cell, Blue star, Cancer, Certification, San Francisco Bay Area, College, Genomics, Epigenomics, FDA, Medical imaging

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP).

Key Points: 
  • Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests focused on non-invasive detection of high-mortality cancers in high-risk patient populations, today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP).
  • CAP Accreditation is an internationally recognized program that awards laboratories that meet stringent requirements of quality, accuracy, and consistency.
  • This milestone further solidifies Bluestar Genomics commitment to providing the highest standards of testing results.
  • Bluestar Genomics pancreatic cancer early detection test has been analytically validated and previously received FDA Breakthrough Device Designation.

$28.8 Billion Worldwide Cell Analysis Industry to 2027 - Featuring Agilent Technologies, BD Biosciences, Danaher and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Neurology, Research, Hospitals, Genetics, Science, Clinical Trials, Epigenomics, Laboratory, COVID-19, Prevalence, Population, Growth, Industry, Investment, Cancer, Non-functional testing, B cell, Neurology, RNA, Research, DNA, Biotechnology, R, Hospital, Conditional sentence, Death, Pharmaceutical industry, Vaccine, Fine chemical, Potash

Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell.

Key Points: 
  • Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell.
  • Cell analysis is typically done to understand population heterogeneity, identifying minority sub-populations of interest, as well as discovering unique characteristics of individual cells.
  • Cell analysis is utilized across academic and research laboratories, hospitals, and biotechnology and pharmaceutical, for studying stem cells, immunology, neurology, non-invasive prenatal diagnosis and in-vitro fertilization.
  • What is the structure of the global cell analysis market and who are the key players?

EQS-News: Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

Retrieved on: 
Monday, September 19, 2022
ECX, Risk, PMA, FDA, Food, AG, Liquid biopsy, Blood, Biomarker, News, Colorectal cancer, CRC, 970, OTCQX, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Physician, EQS, CEO, Technology, Clinical, DNA, Communication, Epigenomics AG, Security (finance), Pharmaceutical industry, Epigenomics

The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.

Key Points: 
  • The prospective, multi-center study titled CRC-DRAW (CRC-Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer.
  • Over the course of the trial, it is expected to enroll over 15,000 subjects to achieve the proposed statistical endpoints needed for the study.
  • Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.
  • Epigenomics' lead product is the blood test Epi proColon for the early detection of colorectal cancer.